Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on May 29, 2024, with the report date reflecting events occurring on May 29 and May 30, 2024. The filing details a registered direct offering and a concurrent private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.0 million raised from the offering.
- Shares Issued: 1,570,683 shares of Common Stock sold at $1.91 per share.
- Warrants Issued:
- Private Placement Warrants: 1,570,683 warrants exercisable at $1.78 per share.
- Agent Warrants: 109,948 warrants issued to the placement agent, exercisable at $2.3875 per share.
- Transaction Costs:
- Placement Agent Cash Fee: 7.0% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Expense Allowance: $35,000 (non-accountable) + $15,950 (clearing fees) + $50,000 (legal expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company's operations.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement (SPA) with institutional investors. Key terms include:
- Lock-Up Period: The Company is restricted from issuing additional Common Stock or equivalents for 60 days following the closing (May 30, 2024), subject to exceptions.
- Registration Obligation: The Company must file a registration statement for the resale of shares underlying the Private Placement Warrants within 30 days of the SPA date and use commercially reasonable efforts to make it effective within 60 to 90 days.
- Beneficial Ownership Limitations: Private Placement Warrants are subject to a 4.99% beneficial ownership limit (increasable to 9.99% with notice).
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds to support working capital needs. The filing includes significant forward-looking statements and risk factors, including:
- Listing Compliance: Risks regarding the ability to regain and maintain compliance with Nasdaq Capital Market listing requirements.
- Cost Reduction: Uncertainty regarding whether the Company's cost reduction plan and workforce reductions will achieve the targeted 50% reduction in cash burn.
- Operational Risks: Challenges in manufacturing products on a commercial scale, securing regulatory approvals, and obtaining future financing on reasonable terms.
- External Factors: Potential impacts of pandemics, economic conditions, and competition.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% total cash fees and specified legal/clearing expenses.
- Confirm the Company's current status regarding Nasdaq Capital Market listing compliance.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants or conditions.
- Monitor the filing of the required Form S-3 registration statement for the warrant shares within the 30-day window.
- Assess the Company's updated cash runway given the stated goal of reducing cash burn by 50%.